Literature DB >> 18187872

Vitamin D status affects osteopenia in postmenopausal patients with primary hyperparathyroidism.

Yoshifumi Inoue1, Hiroshi Kaji, Itoko Hisa, Takako Tobimatsu, Junko Naito, Mei-Fway Iu, Toshitsugu Sugimoto, Kazuo Chihara.   

Abstract

Controversy still exists about whether vitamin D status is related to the severity of primary hyperparathyroidism (pHPT), although vitamin D insufficiency is frequent in pHPT. The present study was therefore performed to examine the relationships between vitamin D status and various parameters in 30 postmenopausal pHPT patients. BMD values were measured by dual-energy x-ray absorptiometry at the lumbar spine (L(2-4)), femoral neck (FN) and distal one third of the radius (Rad 1/3). Serum levels of 25 hydroxy-vitamin D(3) [25(OH)D] and 1,25-dihydroxy vitamin D(3) [1,25(OH) (2)D(3)] were 15.8 +/- 3.5 microg/l and 69.3 +/- 33.3 ng/l in pHPT patients, respectively. Serum levels of calcium and PTH seemed to be negatively correlated to serum 25(OH)D levels, although the differences were not significant. However, when subjects with the highest serum PTH levels (PTH>1000 pg/ml) were excluded from the analysis, the correlation was significant between serum 25(OH)D levels and PTH, indicating that vitamin D status affects the severity of pHPT when severe cases were excluded. In addition, serum levels of 1,25(OH)(2)D(3) were significantly and negatively correlated to serum 25(OH)D levels. On the other hand, serum levels of 25(OH)D were significantly and positively correlated to BMD (Z-score) at the lumbar spine, but not at the radius and femoral neck; however, serum 25(OH)D levels were not correlated to the levels of any bone metabolic indices measured. Moreover, serum levels of 25(OH)D were not related to urinary calcium and the tubular reabsorption rate of phosphorus, and they were similar in groups with and without renal stones. In conclusion, vitamin D status seemed to be related to the severity of disease in postmenopausal patients with pHPT. In particular, the relationship between serum 25(OH)D level and BMD at the lumbar spine was predominant.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18187872     DOI: 10.1507/endocrj.k07-102

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  7 in total

1.  Vitamin D in Primary Hyperparathyroidism: Effects on Clinical, Biochemical, and Densitometric Presentation.

Authors:  Marcella D Walker; Elaine Cong; James A Lee; Anna Kepley; Chiyuan Zhang; Donald J McMahon; Shonni J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2015-06-16       Impact factor: 5.958

2.  Biochemical effects of calcifediol supplementation in mild, asymptomatic, hyperparathyroidism with concomitant vitamin D deficiency.

Authors:  M Luisa Isidro; Belén Ruano
Journal:  Endocrine       Date:  2009-07-14       Impact factor: 3.633

3.  Fasting plasma glucose levels are related to bone mineral density in postmenopausal women with primary hyperparathyroidism.

Authors:  Itoko Hisa; Hiroshi Kaji; Yoshifumi Inoue; Toshitsugu Sugimoto; Kazuo Chihara
Journal:  Int J Clin Exp Med       Date:  2008-09-22

4.  Impact of vitamin D deficiency on the clinical and biochemical phenotype in women with sporadic primary hyperparathyroidism.

Authors:  Giuseppe Viccica; Filomena Cetani; Edda Vignali; Mario Miccoli; Claudio Marcocci
Journal:  Endocrine       Date:  2016-03-31       Impact factor: 3.633

Review 5.  Primary hyperparathyroidism.

Authors:  Marcella D Walker; Shonni J Silverberg
Journal:  Nat Rev Endocrinol       Date:  2017-09-08       Impact factor: 43.330

6.  Prevalence of Vitamin D Inadequacy in Urolithiasis Patients.

Authors:  Kunal Dholakia; Nivash Selvaraj; Narasimhan Ragavan
Journal:  Cureus       Date:  2021-06-01

7.  Vitamin d status in patients operated for primary hyperparathyroidism: comparison of patients from southern and northern europe.

Authors:  Erik Nordenström; Antonio Sitges-Serra; Joan J Sancho; Mark Thier; Martin Almquist
Journal:  Int J Endocrinol       Date:  2013-08-05       Impact factor: 3.257

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.